A dynamic, multiple-biomarker approach aiming for individualized treatment of heart failure with preserved ejection fraction

A dynamic, multiple-biomarker approach aiming for individualized treatment of heart failure with preserved ejection fraction - ADAPT-HFpEF

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON51533

Enrollment

200

Registered

2022-09-02

Start date

2022-11-25

Completion date

Unknown

Last updated

2024-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart failure

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Age of 18 years or older AND - Capable of understanding and signing informed consent AND - A diagnosis of HFpEF according to the HFA-PEFF diagnostic algorithm of the ESC, OR - a high (90%) probability of HFpEF according to the H2FPEF score, i.e. a score of 6 or higher

Exclusion criteria

Exclusion criteria: -History of LVEF

Design outcomes

Primary

Measure	Time frame
The primary endpoint is a combined endpoint of urgent visit resulting in intravenous therapy for HF, hospital readmission for acute or worsened HF, and cardiovascular death.	—

Secondary

Measure	Time frame
The secondary endpoints are: - the separate components of the combined primary endpoint; urgent visit resulting in intravenous therapy for heart failure, hospital readmission for acute or worsened HF, and cardiovascular death. - The combined endpoint urgent visit resulting in intravenous therapy for HF, hospital readmission for acute or worsened HF, and all-cause death. - All-cause death - Myocardial infarction (fatal and non-fatal), stroke (fatal and non-fatal), percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) - Cardiovascular disease (includes all of the above, except all-cause death)	—

Measure

Time frame

The secondary endpoints are: - the separate components of the combined primary endpoint; urgent visit resulting in intravenous therapy for heart failure, hospital readmission for acute or worsened HF, and cardiovascular death. - The combined endpoint urgent visit resulting in intravenous therapy for HF, hospital readmission for acute or worsened HF, and all-cause death. - All-cause death - Myocardial infarction (fatal and non-fatal), stroke (fatal and non-fatal), percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) - Cardiovascular disease (includes all of the above, except all-cause death)

—

Countries

Netherlands

Outcome results